Thrombocytopenia
Exa-cel a ‘first step’ in gene therapy for sickle cell disease, beta-thalassemia
Exagamglogene autotemcel gave most patients with beta-thalassemia transfusion independence and drastically reduced the number of vaso-occlusive crises in those with sickle cell disease in a pair of phase 3 trials.
FDA approves Besponsa for certain pediatric patients with advanced leukemia
The FDA approved inotuzumab ozogamicin for use in pediatric patients with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia, according to a press release.
Immunotherapy combination induces ‘robust’ responses in high-risk follicular lymphoma
SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data presented at ASH Annual Meeting and Exposition.
VIDEO: Treatment considerations for patients with low-, high-risk MDS
Healio spoke with Akriti Jain, MD, about aproaching the treatment of myelodysplastic syndrome based on where patients lie on the MDS spectrum.
Combination yields ‘promising PFS outcomes’ in certain patients with breast cancer
SAN ANTONIO — The combination of zanidatamab, palbociclib and fulvestrant yielded promising PFS results among adults with HER2-positive/hormone receptor-positive metastatic breast cancer, findings from a phase 2A study showed.
Lower platelet count a predictor for ruxolitinib-induced thrombocytopenia
BET inhibitors combined with JAK inhibitors well-tolerated with myelofibrosis
VIDEO: Ruxolitinib plus navitoclax yields ‘challenging’ results in myelofibrosis
In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.
Study yields 'encouraging' preliminary data for navitoclax combination in myelofibrosis
SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.
AI tool addresses ‘clinical conundrum’ by accurately identifying rare blood cancers
SAN DIEGO — An international group of researchers developed an artificial intelligence-based algorithm that differentiates prefibrotic primary myelofibrosis from essential thrombocythemia during pathological analysis, study findings showed.